Science
There’s a significant patient population that’s been hiding in plain sight: cancer patients who have background metabolic dysfunction.
Their metabolic dysfunction has been shown to increase mortality from cancer, but physicians lack effective tools to treat patients with this quite common combination of conditions. That’s where SynDevRx steps in.
SynDevRx brings new tools and fresh thinking to cancer treatment.
We’re developing novel treatments directed specifically towards cancer patients that also have baseline metabolic complications (overweight/obesity, pre-diabetes, T2D). Research shows that improving cancer patients’ metabolic state improves outcomes, but it’s a challenge!
By offering treating oncologists and physicians a simple once-every-two-week subcutaneous injection to their patients that address a major unmet medical need (baseline metabolic dysfunction) we hypothesize we can potentiate standard-of-care treatments for a wide variety of cancers, including breast, prostate, colorectal, liver among others.
Our drug development strategy has three-parts:
1. start with a validated class of drug that has demonstrated clinical activity in cancer and obesity – but had a toxicity problem;
2. tackle the toxicity issues while maintaining drug activity via polymer-drug conjugation; and
3. improve the doctor and patient experience by delivering this new drug on a simple Q14D basis with relatively low volume of infusion.
Metabo-oncology
The link between metabolic dysfunction and cancer outcomes is undeniable. SynDevRx is the leader in the emerging metabo-oncology field of drug development, and our first clinical drug candidate targets a patient population that comprises millions of new cancer cases around the world each year. Learn about metabo-oncology, the newest addition to the armamentarium of cancer treatment.
Explore
Polymer-Drug Conjugation
In 1975, Helmut Ringsdorf first suggested that attaching active small molecules to biocompatible polymers could improve drug properties. Many companies have since come close to realizing his vision but failed. With our novel approach to polymer-drug conjugates, SynDevRx has uncovered the key to success. Learn about our polymer-drug conjugation approach.
Explore
MetAP2 – Validated in Cancer and in Obesity
The molecular target for our novel fumagillin-polymer conjugates — methionine aminopeptidase type II (MetAP2) — is a key mediator in various conditions related to hypoxia, cell cycle arrest, angiogenesis and chronic inflammation. See why MetAP2 inhibition could help in treating many cancer types, morbid obesity and other diseases.
Explore